Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in Combination With Chemotherapy and Radiotherapy for Local Advanced Nasopharyngeal Cancer
NCT01074021Phase 3Unknown
- Start
- Oct 2009
- Primary completion
- May 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngeal carcinoma (NPC) comparing Nimotuzumab plus chemoradiotherapy with Placebo plus chemoradiotherapy (2 arms). Primary endpoints: Local-regional control rates and Safety of the treatment. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT01074021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01074021.